Study on oxaliplatin plus S-1 versus XELOX program in adjuvant chemotherapy of postoperative gastric cancer
10.3969/j.issn.1671-8348.2013.26.011
- VernacularTitle:奥沙利铂联合替吉奥在胃癌术后辅助化疗中的研究
- Author:
Xiaofei ZHANG
;
Kang YANG
;
Xianxu SU
- Publication Type:Journal Article
- Keywords:
gastric neoplasms;
antineoplastic combined chemotherapy protocots;
oxaliplatin
- From:
Chongqing Medicine
2013;(26):3107-3109
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of oxaliplatin plus S-1 versus the XELOX(oxaliplatin + capecitabine) program in the adjuvant chemotherapy in the patients with postoperative gastric cancer .Methods A total of 81 cases with postoperative gas-tric cancer were randomly divided into the treatment group and the control group .The treatment group (41 cases) received the chemotherapy of oxaliplatin +S-1 ,while control group was given the chemotherapy of XEOLX program .Results The 1-year and 2-year recurrence-free survival (RFS) of the treatment group and the control group were 51 .3% vs .61 .5% ,25 .6% vs .20 .5% ,there were no statistically significant differences between the two groups (P=0 .361 ,P=0 .591) .The 1-year and 2-year overall survival period of the treatment group and the control group were 64 .1% vs .69 .2% ,30 .8% vs .25 .6% ,respectively ,there were also no sta-tistically significant differences between two groups(P=0 .631 ,P=0 .615) .The mainly adverse reactions of the two groups were myelosuppression ,gastrointestinal reactions ,hand-foot syndrome ,mucositis ,peripheral nerve toxicity ,hepatic and renal function damage .The occurrence rate of hand-foot syndrome in the control group was significantly higher than that in the treatment group (P=0 .001) ,the adverse reactions were improved after symptomatic treatment .Conclusion Oxaliplatin plus S-1 and oxaliplatin plus capecitabine are therapeutic equivalence and well tolerated in the patients with postoperative gastric cancer .
